Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 3Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer 1Pancreatic Neoplasms 1Locally Advanced Colorectal Cancer 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Colorectal Cancer Metastatic 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

Gastrectomy 4apatinib 3Taxes 3S 1 (combination) 3Oxaliplatin 3Cisplatin 3sintilimab 2Paclitaxel 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Docetaxel 2Albumin-Bound Paclitaxel 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tipiracil 1taxane 1pembrolizumab 1durvalumab 1disitamab vedotin 1cabozantinib 1andecaliximab 1XELOX 1Trifluridine 1Tegafur 1Tadalafil 1SHR-1701 1Resistance Training 1Radiotherapy 1Platinum 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric Adenocarcinoma × SHR-1701 × Gastrointestinal × Clear all
NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡